| Burge, Matthew |
| Active, not recruiting | 3 | 450 | Europe, Japan, US, RoW | Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf | Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health | Gastro-Oesophageal Cancer | 06/25 | 06/26 | | |
ACTRN12607000604404: A study looking at the effect positron emission tomography (PET) scans have on the treatment decisions specialists make in patients with suspected cancer of the pancreas. |
|
|
| Recruiting | 2 | 90 | | | Royal Brisbane Hospital, Royal Brisbane Hospital | Pancreatic and peri-ampullary cancers. | | | | |
ACTRN12618000233224: MONARCC: A randomised phase II study of Panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer. |
|
|
| Active, not recruiting | 2 | 80 | | | AGITG, Amgen | metastatic colorectal cancer | | | | |
NCT06441747: Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) |
|
|
| Recruiting | 2 | 40 | RoW | Durvalumab, Imfinzi, Olaparib, Lynparza | Australasian Gastro-Intestinal Trials Group, Wayne Elphinstone Research Fund, AstraZeneca | Cholangiocarcinoma | 08/26 | 08/28 | | |
STOPNET, NCT06345079: Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours |
|
|
| Recruiting | 2 | 78 | Canada, RoW | Cessation of somatostatin analogues, SSA cessation, Continuation of somatostatin analogues, SSA continuation | Australasian Gastro-Intestinal Trials Group, Canadian Cancer Trials Group | Neuroendocrine Tumors | 09/27 | 06/28 | | |
NCT00819208: Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer |
|
|
| Active, not recruiting | N/A | 889 | Europe, Canada, US, RoW | exercise intervention, counseling intervention, educational intervention, laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, fatigue assessment and management, quality-of-life assessment, Educational Intervention, Fitness testing | Canadian Cancer Trials Group, Survivorship Research Group, Queen's University, Belfast | Anxiety Disorder, Cognitive/Functional Effects, Colorectal Cancer, Depression, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Sleep Disorders, Excercise | 12/29 | 12/30 | | |
ACTRN12617000596303: A Pilot Study of CXCR-4 (68Ga-CPCR4-2) PET (Positron Emission Tomography) scanning in operable rectal cancer |
|
|
| Not yet recruiting | N/A | 12 | | | Royal Brisbane and Women's Hospital, Royal Brisbane and Women's Hospital Herston Imaging Research Facility Seed Funding | Rectal Adenocarcinoma | | | | |
| Not yet recruiting | N/A | 24 | | | Royal Brisbane and Women's Hospital, Royal Brisbane and Women's Hospital Herston Imaging Research Facility Seed Funding | Pancreatic Adenocarcinoma | | | | |
| Tie, Jeanne |
ACTRN12617001566325: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study (DYNAMIC-III) |
|
|
| Recruiting | 2/3 | 1000 | | | Australasian Gastro-Intestinal Trials Group, Marcus Foundation | Colorectal Cancer | | | | |
RESOLUTE, NCT05862051: Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 75 | RoW | Local Ablative Therapy, Standard first-line systemic treatment | Australasian Gastro-Intestinal Trials Group, Walter and Eliza Hall Institute of Medical Research, Cancer Council Victoria | Colorectal Cancer, Oligometastatic Disease | 06/24 | 06/25 | | |
SYLVER, NCT06710847: A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors |
|
|
| Recruiting | 1/2 | 73 | Japan, US | GSK4418959, PD-1 inhibitor | GlaxoSmithKline, IDEAYA Biosciences | Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer, Endometrial Cancer | 02/27 | 06/28 | | |
IGM-8444-001, NCT04553692: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers |
|
|
| Active, not recruiting | 1 | 272 | Europe, US, RoW | Aplitabart (IGM-8444), FOLFIRI, Fluorouracil or 5-FU, Leucovorin, Irinotecan, Bevacizumab (and approved biosimilars), Avastin, Birinapant, Venetoclax, Venclexta, Gemcitabine, Gemzar, Docetaxel, Taxotere, Docefrez, Azacitidine, VIDAZA | IGM Biosciences, Inc. | Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia | 06/26 | 08/27 | | |
ACTRN12612000327886: Circulating Tumour DNA as a Marker of Complete Pathological Response and Long Term Outcome for Locally Advanced Rectal Cancer Treated with Pre-operative Chemoradiotherapy |
|
|
| Not yet recruiting | N/A | 320 | | | Ludwig Institute for Cancer Research, National Health and medical Coucil | Patients with locally advanced rectal cancer planned for pre-operative CRT followed by definitive surgery and post operative chemotherapy., Nil | | | | |
ACTRN12612000345886: Circulating Tumour DNA as a Sensitive and Specific Marker of Response to Therapy and of Occult Disease in Colorectal Cancer |
|
|
| Recruiting | N/A | 100 | | | Ludwig Institute for Cancer Research, Ludwig Institute for Cancer Research | Patients with resectable colorectal cancer liver metastases | | | | |
ACTRN12612000326897: Circulating Tumour DNA as a Marker of Occult Disease in Stage II Colorectal Cancer and Response to Therapy in Metastatic Colorectal Cancer |
|
|
| Recruiting | N/A | 290 | | | Ludwig Institute for Cancer Research, Ludwig Institute for Cancer Research | Measuring cancer specific gene changes in the blood as a biomarker in monitoring disease status in stage II and IV colorectal cancer. | | | | |
| Recruiting | N/A | 1000 | | | The Walter and Eliza Hall Institute of Medical Research (WEHI), The Walter and Eliza Hall Institute of Medical Research (WEHI) | Colorectal cancer, Benign bowel disease | | | | |
ACTRN12621001198819: A Phase II Trial to Evaluate the Strategy of Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer (RESOLUTE) |
|
|
| Recruiting | N/A | 50 | | | Cancer Council Victoria, Cancer Council Victoria, The Australasian Gastro-Intestinal Cancer Trials Group | metastatic colorectal cancer | | | | |
ACTRN12615000770561: Evaluation of RAS mutations in cell free deoxyribonucleic acid (cfDNA) in response to cetuximab anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer. |
|
|
| Active, not recruiting | N/A | 36 | | | The Walter and Eliza Hall Institute of Medical Research, Sysmex Inostics, Inc. | Patients with histologically confirmed metastatic colorectal cancer. | | | | |
ACTRN12615000381583: Circulating tumour DNA (ctDNA) analysis informing adjuvant chemotherapy in Stage II Colon Cancer |
|
|
| Active, not recruiting | N/A | 450 | | | Walter and Eliza Hall Institute, NHMRC | Patients with the diagnosis of Stage II Colon cancer., Patients with the diagnosis of stage II rectal cancer | | | | |
| Vora |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
| Costello |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
CARTITUDE-6, NCT05257083 / 2021-003284-10: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma |
|
|
| Recruiting | 3 | 750 | Europe, Canada, Japan, US, RoW | Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine | Stichting European Myeloma Network, Janssen Research & Development, LLC | Multiple Myeloma | 06/33 | 08/40 | | |
| Health, Western |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
| Henderson, Stephanie |
RESOLUTE, NCT05862051: Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 75 | RoW | Local Ablative Therapy, Standard first-line systemic treatment | Australasian Gastro-Intestinal Trials Group, Walter and Eliza Hall Institute of Medical Research, Cancer Council Victoria | Colorectal Cancer, Oligometastatic Disease | 06/24 | 06/25 | | |
